Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors
Biogen Inc. (Nasdaq: BIIB) is a leading neuroscience biotech known for multiple sclerosis and rare-disease therapies ts2.tech. On Oct. 30, 2025 the stock dipped after a mixed earnings release. The company beat Q3 expectations – adjusted EPS $4.81 vs. $3.88 est and $2.53 B revenue vs. $2.34 B est Investing – but lowered its full-year outlook. Biogen now expects 2025 non-GAAP EPS…